World Pharma Congress 2014 | Chemical Route Development of HCV Protease-Inhibitor

Dr. Gerald Tanoury from Vertex, featured speaker at CHI's 'Efficient Process Chemistry' meeting May 22-24, 2014 in Boston, speaks about dealing with two challenging chemical steps in the scale-up of HCV protease inhibitor, Telaprevir, which was launched in 2011 as a new treatment for hepatitis C infection. Tanoury also discusses Telaprevir's route development in the context of his views on what makes an efficient route and shares with the interviewer, Dr. Anjani Shah, Conference Director for CHI, what he is interested in learning more about at the meeting.